Abstract: An ultrasound-based handheld animal and plant tissue ablation instrument includes a housing internally provided with a control board and a drive board, and an ultrasonic vibrator fixedly connected to a front end of the housing. The ultrasonic vibrator includes an ultrasonic transducer and an amplitude transformer. The amplitude transformer is fixedly connected to a front end of the ultrasonic transducer, changes an amplitude of vibration input by the ultrasonic transducer and transmits out the vibration. The control board is provided with a power supply, a DCDC conversion unit, a main control unit, a DCDC power adjustment unit and a sampling unit. The drive board is provided with a drive unit, a transformer unit and a resonance unit. The housing includes a first section and a second section. The end of the first section away from the second section is the front end of the housing.

Abstract: In the invention, the minimum inhibitory concentrations of human coagulation factor light-chain proteins against different Gram-negative bacteria are detected with the in vitro antibacterial activity and the inhibiting effect of the human coagulation factor light-chain proteins against different Gram-negative bacteria is detected with the in vivo antibacterial activity. It has been shown that human coagulation factor light-chain proteins have an obvious inhibitory effect on the Gram-negative bacteria, so as to develop a novel class of medicaments for treating Gram-negative bacteria infection. It has been demonstrated by mass spectrometry and silver staining that human coagulation factor light-chain proteins have the effect on hydrolyzing and eliminating the endotoxin, which facilitates the development of a novel class of medicaments for treating endotoxemia.

Abstract: In the invention, the minimum inhibitory concentrations of human coagulation factor light-chain proteins against different Gram-negative bacteria are detected with the in vitro antibacterial activity and the inhibiting effect of the human coagulation factor light-chain proteins against different Gram-negative bacteria is detected with the in vivo antibacterial activity. It has been shown that human coagulation factor light-chain proteins have an obvious inhibitory effect on the Gram-negative bacteria, so as to develop a novel class of medicaments for treating Gram-negative bacteria infection. It has been demonstrated by mass spectrometry and silver staining that human coagulation factor light-chain proteins have the effect on hydrolyzing and eliminating the endotoxin, which facilitates the development of a novel class of medicaments for treating endotoxemia.